Mineralys Therapeutics, Inc. ( (MLYS) ) has shared an update.
Mineralys Therapeutics, Inc. has successfully completed the target enrollment for its Advance-HTN trial, with 261 subjects signed up to test the efficacy and safety of lorundrostat in treating resistant and uncontrolled hypertension. The trial is a key step in the development of lorundrostat, which aims to offer improved cardiovascular risk management for patients not meeting blood pressure goals through current medications. Top-line data from the trial is anticipated in the first quarter of 2025, with ongoing enrollment for additional subjects in screening or run-in phases. The company is hosting a virtual KOL event to discuss the unmet needs in hypertension treatment and provide insights into the ongoing clinical program for lorundrostat.
For an in-depth examination of MLYS stock, go to TipRanks’ Stock Analysis page.
